David S Cooper1, Donna Claes2, Stuart L Goldstein3, Michael R Bennett2, Qing Ma2, Prasad Devarajan2, Catherine D Krawczeski3. 1. Department of Pediatrics, The Heart Institute, Division of Cardiology and Center for Acute Care Nephrology, Division of Nephrology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio David.Cooper@cchmc.org. 2. Center for Acute Care Nephrology, Division of Nephrology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio. 3. Department of Pediatrics, The Heart Institute, Division of Cardiology and Center for Acute Care Nephrology, Division of Nephrology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Abstract
BACKGROUND AND OBJECTIVES: Novel urinary kidney damage biomarkers detect AKI after cardiac surgery using cardiopulmonary bypass (CPB-AKI). Although there is growing focus on whether AKI leads to CKD, no studies have assessed whether novel urinary biomarkers remain elevated long term after CPB-AKI. We assessed whether there was clinical or biomarker evidence of long-term kidney injury in patients with CPB-AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a cross-sectional evaluation for signs of chronic kidney injury using both traditional measures and novel urinary biomarkers in a population of 372 potentially eligible children (119 AKI positive and 253 AKI negative) who underwent surgery using cardiopulmonary bypass for congenital heart disease at Cincinnati Children's Hospital Medical Center between 2004 and 2007. A total of 51 patients (33 AKI positive and 18 AKI negative) agreed to long-term assessment. We also compared the urinary biomarker levels in these 51 patients with those in healthy controls of similar age. RESULTS: At long-term follow-up (mean duration±SD, 7±0.98 years), AKI-positive and AKI-negative patients had similarly normal assessments of kidney function by eGFR, proteinuria, and BP measurement. However, AKI-positive patients had higher urine concentrations of IL-18 (48.5 pg/ml versus 20.3 pg/ml [P=0.01] and 20.5 pg/ml [P<0.001]) and liver-type fatty acid-binding protein (L-FABP) (5.9 ng/ml versus 3.9 ng/ml [P=0.001] and 3.2 ng/ml [P<0.001]) than did AKI-negative patients and healthy controls. CONCLUSIONS: Novel urinary biomarkers remain elevated 7 years after an episode of CPB-AKI in children. However, there is no conventional evidence of CKD in these children. These biomarkers may be a more sensitive marker of chronic kidney injury after CPB-AKI. Future studies are needed to understand the clinical relevance of persistent elevations in IL-18, kidney injury molecule-1, and L-FABP in assessments for potential long-term kidney consequences of CPB-AKI.
BACKGROUND AND OBJECTIVES: Novel urinary kidney damage biomarkers detect AKI after cardiac surgery using cardiopulmonary bypass (CPB-AKI). Although there is growing focus on whether AKI leads to CKD, no studies have assessed whether novel urinary biomarkers remain elevated long term after CPB-AKI. We assessed whether there was clinical or biomarker evidence of long-term kidney injury in patients with CPB-AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We performed a cross-sectional evaluation for signs of chronic kidney injury using both traditional measures and novel urinary biomarkers in a population of 372 potentially eligible children (119 AKI positive and 253 AKI negative) who underwent surgery using cardiopulmonary bypass for congenital heart disease at Cincinnati Children's Hospital Medical Center between 2004 and 2007. A total of 51 patients (33 AKI positive and 18 AKI negative) agreed to long-term assessment. We also compared the urinary biomarker levels in these 51 patients with those in healthy controls of similar age. RESULTS: At long-term follow-up (mean duration±SD, 7±0.98 years), AKI-positive and AKI-negative patients had similarly normal assessments of kidney function by eGFR, proteinuria, and BP measurement. However, AKI-positive patients had higher urine concentrations of IL-18 (48.5 pg/ml versus 20.3 pg/ml [P=0.01] and 20.5 pg/ml [P<0.001]) and liver-type fatty acid-binding protein (L-FABP) (5.9 ng/ml versus 3.9 ng/ml [P=0.001] and 3.2 ng/ml [P<0.001]) than did AKI-negative patients and healthy controls. CONCLUSIONS: Novel urinary biomarkers remain elevated 7 years after an episode of CPB-AKI in children. However, there is no conventional evidence of CKD in these children. These biomarkers may be a more sensitive marker of chronic kidney injury after CPB-AKI. Future studies are needed to understand the clinical relevance of persistent elevations in IL-18, kidney injury molecule-1, and L-FABP in assessments for potential long-term kidney consequences of CPB-AKI.
Authors: A Akcan-Arikan; M Zappitelli; L L Loftis; K K Washburn; L S Jefferson; S L Goldstein Journal: Kidney Int Date: 2007-03-28 Impact factor: 10.612
Authors: Andrea Lassnigg; Daniel Schmidlin; Mohamed Mouhieddine; Lucas M Bachmann; Wilfred Druml; Peter Bauer; Michael Hiesmayr Journal: J Am Soc Nephrol Date: 2004-06 Impact factor: 10.121
Authors: Denise C Hasson; John T Brinton; Ellen Cowherd; Danielle E Soranno; Katja M Gist Journal: Pediatr Crit Care Med Date: 2019-07 Impact factor: 3.624
Authors: Jason H Greenberg; Prasad Devarajan; Heather R Thiessen-Philbrook; Catherine Krawczeski; Chirag R Parikh; Michael Zappitelli Journal: Pediatr Nephrol Date: 2018-03-06 Impact factor: 3.714
Authors: Michael Zappitelli; Chirag R Parikh; James S Kaufman; Alan S Go; Paul L Kimmel; Chi-Yuan Hsu; Steven G Coca; Vernon M Chinchilli; Jason H Greenberg; Marva M Moxey-Mims; T Alp Ikizler; Vedran Cockovski; Anne-Marie Dyer; Prasad Devarajan Journal: Clin J Am Soc Nephrol Date: 2020-09-18 Impact factor: 8.237
Authors: Jason H Greenberg; Michael Zappitelli; Prasad Devarajan; Heather R Thiessen-Philbrook; Catherine Krawczeski; Simon Li; Amit X Garg; Steve Coca; Chirag R Parikh Journal: JAMA Pediatr Date: 2016-11-01 Impact factor: 16.193
Authors: Bryan H Goldstein; Stuart L Goldstein; Prasad Devarajan; Farhan Zafar; David M Kwiatkowski; Bradley S Marino; David L S Morales; Catherine D Krawczeski; David S Cooper Journal: Cardiol Young Date: 2017-09-11 Impact factor: 1.093